And EGFR‐TKI could not only inhibit tumor cell viability but also enhance antitumor immunity via reducing PD‐L1 expression level,[232] for example, gefitinib can reduce PD‐L1 expression via inhibiting NF‐κB signaling in EGFRmut tumors.[234] Therefore, EGFR activation promotes PD‐L1 expression via NF‐κB signaling. Here, NFKB1 is linked to neoplasm.